Quantum Computing, Inc. Announces Collaboration with Sanders Tri-Institutional Therapeutics Discovery Institute To Support Research Using Dirac-3 Systems
Quantum Computing Inc. (QUBT) has announced a strategic collaboration with Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI) to advance computational biomedicine research. Through this partnership, QCi will provide Sanders TDI with cloud-based access to its Dirac-3 Entropy Quantum Computing Machine, which operates at room temperature and low power.
Sanders TDI, a New York City-based non-profit drug discovery institute comprising Kettering Cancer Center, The Rockefeller University, and Memorial Sloan Weill Cornell Medicine, will utilize QCi's quantum computation technology for experimental work. The collaboration aims to advance computational chemistry research through quantum-enabled applications, focusing on biomolecular modeling and proof of concept calculations.
The partnership demonstrates QCi's commitment to making quantum machines accessible and affordable while showcasing real-world applications of quantum computing technology.
Quantum Computing Inc. (QUBT) ha annunciato una collaborazione strategica con Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI) per promuovere la ricerca in biomedicina computazionale. Attraverso questa partnership, QCi fornirà a Sanders TDI accesso basato su cloud alla sua Dirac-3 Entropy Quantum Computing Machine, che funziona a temperatura ambiente e a basso consumo energetico.
Sanders TDI, un istituto di ricerca non profit con sede a New York che comprende il Kettering Cancer Center, la Rockefeller University e il Memorial Sloan Weill Cornell Medicine, utilizzerà la tecnologia di calcolo quantistico di QCi per lavori sperimentali. La collaborazione ha l'obiettivo di avanzare la ricerca in chimica computazionale attraverso applicazioni abilitate dal quantistico, concentrandosi sulla modellazione biomolecolare e sui calcoli di prova di concetto.
La partnership dimostra l'impegno di QCi nel rendere accessibili e convenienti le macchine quantistiche, mentre mette in luce applicazioni pratiche della tecnologia di calcolo quantistico.
Quantum Computing Inc. (QUBT) ha anunciado una colaboración estratégica con Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI) para avanzar en la investigación en biomedicina computacional. A través de esta asociación, QCi proporcionará a Sanders TDI acceso basado en la nube a su Dirac-3 Entropy Quantum Computing Machine, que funciona a temperatura ambiente y con bajo consumo de energía.
Sanders TDI, un instituto de descubrimiento de fármacos sin fines de lucro con sede en la ciudad de Nueva York, que comprende el Kettering Cancer Center, la Universidad Rockefeller y el Memorial Sloan Weill Cornell Medicine, utilizará la tecnología de computación cuántica de QCi para trabajos experimentales. La colaboración tiene como objetivo avanzar en la investigación de química computacional a través de aplicaciones basadas en la cuántica, centrándose en la modelización biomolecular y en cálculos de prueba de concepto.
La asociación demuestra el compromiso de QCi por hacer accesibles y asequibles las máquinas cuánticas, mientras muestra aplicaciones del mundo real de la tecnología de computación cuántica.
Quantum Computing Inc. (QUBT)는 Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI)와 전략적 협력을 발표하여 컴퓨터 생물 의학 연구를 발전시키고자 합니다. 이 파트너십을 통해 QCi는 Sanders TDI에 클라우드 기반의 Dirac-3 Entropy Quantum Computing Machine에 대한 접근을 제공할 예정입니다. 이 기계는 실온에서 작동하며 저전력으로 운영됩니다.
Sanders TDI는 케터링 암 센터, 록펠러 대학교, 메모리얼 슬론 와일 코넬 의과대학으로 구성된 뉴욕 시 기반의 비영리 약물 발견 연구소로, QCi의 양자 계산 기술을 실험 작업에 사용할 것입니다. 이 협력은 양자 가능 응용 프로그램을 통해 계산 화학 연구를 촉진하는 것을 목표로 하며, 생체 분자 모델링 및 개념 증명 계산에 중점을 두고 있습니다.
이번 파트너십은 QCi가 양자 기계를 접근 가능하고 저렴하게 만들겠다는 의지를 보여주며, 양자 컴퓨팅 기술의 실제 응용 사례를 보여줍니다.
Quantum Computing Inc. (QUBT) a annoncé une collaboration stratégique avec Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI) pour faire avancer la recherche en biomedicine computationnelle. Grâce à ce partenariat, QCi fournira à Sanders TDI un accès basé sur le cloud à sa Dirac-3 Entropy Quantum Computing Machine, qui fonctionne à température ambiante et à faible consommation d'énergie.
Sanders TDI, un institut à but non lucratif de découverte de médicaments basé à New York, comprenant le Kettering Cancer Center, la Rockefeller University et le Memorial Sloan Weill Cornell Medicine, utilisera la technologie de calcul quantique de QCi pour des travaux expérimentaux. L'objectif de la collaboration est de faire avancer la recherche en chimie computationnelle à travers des applications habilitées par la quantique, en se concentrant sur la modélisation biomoléculaire et les calculs de preuves de concept.
Ce partenariat démontre l'engagement de QCi à rendre les machines quantiques accessibles et abordables tout en mettant en avant des applications concrètes de la technologie de calcul quantique.
Quantum Computing Inc. (QUBT) hat eine strategische Zusammenarbeit mit Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI) bekannt gegeben, um die Forschung in der computergestützten Biomedizin voranzutreiben. Im Rahmen dieser Partnerschaft wird QCi Sanders TDI cloudbasierten Zugang zu seiner Dirac-3 Entropy Quantum Computing Machine gewähren, die bei Raumtemperatur und mit geringem Energieverbrauch betrieben wird.
Sanders TDI, ein gemeinnütziges Institut für Arzneimittelentdeckung mit Sitz in New York City, das das Kettering Cancer Center, die Rockefeller University und das Memorial Sloan Weill Cornell Medicine umfasst, wird die Quantenberechnungstechnologie von QCi für experimentelle Arbeiten nutzen. Ziel der Zusammenarbeit ist es, die Forschung in der computergestützten Chemie durch quantengestützte Anwendungen voranzubringen, wobei der Fokus auf biomolekularer Modellierung und Machbarkeitsberechnungen liegt.
Die Partnerschaft zeigt QCi's Engagement, Quantenmaschinen zugänglich und erschwinglich zu machen und gleichzeitig reale Anwendungen der Quantencomputing-Technologie zu demonstrieren.
- Strategic collaboration with prestigious medical research institutions
- Expansion into biomedical and pharmaceutical research applications
- Demonstration of real-world commercial applications for QCi's technology
- None.
Insights
This collaboration marks a strategic pivot into the biomedical research sector for QCi's Dirac-3 quantum computing platform. The partnership with Sanders TDI, which brings together three prestigious medical institutions, positions QCi's room-temperature quantum systems for real-world applications in drug discovery and computational biomedicine. The key technical advantage of Dirac-3's ability to operate at room temperature and low power significantly reduces operational costs compared to traditional quantum computers requiring cryogenic cooling.
The collaboration's focus on computational chemistry and biomolecular modeling represents a high-value market opportunity. Drug discovery typically costs pharmaceutical companies
For investors, this partnership validates QCi's technology in a practical, revenue-generating application while opening doors to the lucrative pharmaceutical research market. However, the announcement lacks specific financial terms or timeline commitments, making immediate revenue impact uncertain.
The integration of QCi's quantum computing capabilities into Sanders TDI's drug discovery platform represents a significant technological advancement in computational biomedicine. Traditional molecular modeling faces limitations with complex protein interactions and drug binding simulations. Quantum computing could potentially solve these computational bottlenecks, particularly in:
- Protein folding predictions
- Drug-target interaction modeling
- Optimization of lead compounds
The collaboration with Sanders TDI, which combines the research power of three leading medical institutions, provides QCi with valuable validation in the pharmaceutical research space. However, quantum computing in drug discovery remains largely experimental and successful implementation will require significant development and validation work. The lack of specific success metrics or development timelines suggests this is still in early exploratory phases.
Sanders TDI is a non-profit drug discovery institute based in
As part of the collaboration, QCi will offer Sanders TDI cloud-based access to its Dirac-3 systems, which operate at room temperature and low power and are designed to solve complex optimization problems.
"We are truly excited to be a part of this strategic collaboration with Sanders TDI and to have our Dirac-3 systems support their efforts in rapidly assessing the efficacy of targeted therapeutics in treating human diseases," stated Dr. William McGann, Chief Executive Officer (CEO) of QCi. "This partnership exemplifies how QCi's quantum machines can provide powerful insights and useful analyses today. It aligns perfectly with our mission to make quantum machines accessible and affordable and is one of the many real-world applications where the power of quantum computing is being demonstrated and put into practice by QCi."
The collaboration will focus on advancing Sanders TDI's computational chemistry research by leveraging quantum technologies, including quantum analog computers, for proof of concept calculations in biomolecular modeling. Recognizing the diverse set of potential use cases in this field, QCi will work closely with Sanders TDI to explore a variety of quantum-enabled applications, with the goal of identifying the most promising use cases for its Dirac systems.
To learn more about how QCi is driving the future of accessible and affordable photonic technology or to explore collaboration opportunities, please visit the QCi webpage.
About Quantum Computing Inc.
Quantum Computing Inc. (Nasdaq: QUBT) is an innovative, integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. QCi's products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer unique capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
For investor relations inquiries, contact John Nesbett at qci@imsinvestorrelations.com, and for public relations inquiries, contact Jessica Tocco at jessica.tocco@a10associates.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," "aim to," or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including the development of biomedical quantum applications, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quantum-computing-inc-announces-collaboration-with-sanders-tri-institutional-therapeutics-discovery-institute-to-support-research-using-dirac-3-systems-302351488.html
SOURCE Quantum Computing Inc.
FAQ
What is the purpose of QUBT's collaboration with Sanders TDI?
How will Sanders TDI access QUBT's Dirac-3 systems?
What institutions are part of Sanders TDI collaborating with QUBT?
What specific applications will QUBT's Dirac-3 systems be used for at Sanders TDI?
What are the technical advantages of QUBT's Dirac-3 systems mentioned in the collaboration?
